Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Rituximab for IgM MGUS or Waldenström Macroglobulinemia Neuropathy
NCT05065554Phase 2Active, not recruiting
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in IgM monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia (WM), peripheral neuropathy. Started Nov 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
IgM monoclonal gammopathy of undetermined significanceWaldenström macroglobulinemia (WM)peripheral neuropathy
Beyond the preview
Go deeper on NCT05065554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065554.